UBS AM’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-53,343
| Closed | -$203K | – | 2578 |
|
|
2020
Q1 | $203K | Sell |
53,343
-3,119
| -6% | -$11.9K | ﹤0.01% | 2276 |
|
|
2019
Q4 | $287K | Sell |
56,462
-3,413
| -6% | -$17.4K | ﹤0.01% | 2380 |
|
|
2019
Q3 | $303K | Buy |
59,875
+12,864
| +27% | +$65K | ﹤0.01% | 2455 |
|
|
2019
Q2 | $290K | Buy |
47,011
+8,704
| +23% | +$53.7K | ﹤0.01% | 2426 |
|
|
2019
Q1 | $178K | Hold |
38,307
| – | – | ﹤0.01% | 2492 |
|
|
2018
Q4 | $161K | Hold |
38,307
| – | – | ﹤0.01% | 2454 |
|
|
2018
Q3 | $240K | Hold |
38,307
| – | – | ﹤0.01% | 2361 |
|
|
2018
Q2 | $308K | Sell |
38,307
-9,548
| -20% | -$76.8K | ﹤0.01% | 2292 |
|
|
2018
Q1 | $357K | Buy |
47,855
+8,306
| +21% | +$62K | ﹤0.01% | 2143 |
|
|
2017
Q4 | $235K | Hold |
39,549
| – | – | ﹤0.01% | 2229 |
|
|
2017
Q3 | $291K | Buy |
39,549
+825
| +2% | +$6.07K | ﹤0.01% | 2094 |
|
|
2017
Q2 | $263K | Hold |
38,724
| – | – | ﹤0.01% | 2086 |
|
|
2017
Q1 | $366K | Buy |
38,724
+11,300
| +41% | +$107K | ﹤0.01% | 1951 |
|
|
2016
Q4 | $237K | Sell |
27,424
-10,438
| -28% | -$90.2K | ﹤0.01% | 2037 |
|
|
2016
Q3 | $240K | Buy |
37,862
+3,762
| +11% | +$23.8K | ﹤0.01% | 2376 |
|
|
2016
Q2 | $144K | Hold |
34,100
| – | – | ﹤0.01% | 2533 |
|
|
2016
Q1 | $149K | Hold |
34,100
| – | – | ﹤0.01% | 2511 |
|
|
2015
Q4 | $209K | Sell |
34,100
-2,800
| -8% | -$17.2K | ﹤0.01% | 2517 |
|
|
2015
Q3 | $211K | Buy |
36,900
+2,800
| +8% | +$16K | ﹤0.01% | 2467 |
|
|
2015
Q2 | $254K | Buy |
+34,100
| New | +$254K | ﹤0.01% | 2462 |
|